This study is for adults with recurrent respiratory papillomatosis (RRP), a condition where wart-like growths develop in the airways. The study is testing a drug called Zopapogene imadenovec (Zopa). The first group will help researchers see if the drug spreads in the body by checking samples like urine and skin. The second group will see how well the drug works in those who've had it before. To join, you must be at least 18, have RRP, and meet other health requirements.
- Study involves two groups, each with 30 participants.
- Participants may need to use birth control for a specific time after treatment.
- Some health conditions or medications may prevent participation.
How understandable was the trial content above?
Hard to understand
Easy to understand